These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15840739)

  • 1. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy.
    Dobnig H; Sipos A; Jiang Y; Fahrleitner-Pammer A; Ste-Marie LG; Gallagher JC; Pavo I; Wang J; Eriksen EF
    J Clin Endocrinol Metab; 2005 Jul; 90(7):3970-7. PubMed ID: 15840739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
    Cosman F; Nieves J; Woelfert L; Shen V; Lindsay R
    J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
    Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
    Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment.
    Fahrleitner-Pammer A; Burr D; Dobnig H; Stepan JJ; Petto H; Li J; Krege JH; Pavo I
    Bone; 2016 Aug; 89():16-24. PubMed ID: 27185100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis.
    Chen P; Miller PD; Recker R; Resch H; Rana A; Pavo I; Sipos AA
    J Bone Miner Res; 2007 Aug; 22(8):1173-80. PubMed ID: 17451369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
    Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial.
    Dempster DW; Zhou H; Recker RR; Brown JP; Bolognese MA; Recknor CP; Kendler DL; Lewiecki EM; Hanley DA; Rao DS; Miller PD; Woodson GC; Lindsay R; Binkley N; Wan X; Ruff VA; Janos B; Taylor KA
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2799-808. PubMed ID: 22701017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters.
    Arlot M; Meunier PJ; Boivin G; Haddock L; Tamayo J; Correa-Rotter R; Jasqui S; Donley DW; Dalsky GP; Martin JS; Eriksen EF
    J Bone Miner Res; 2005 Jul; 20(7):1244-53. PubMed ID: 15940379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
    Body JJ; Gaich GA; Scheele WH; Kulkarni PM; Miller PD; Peretz A; Dore RK; Correa-Rotter R; Papaioannou A; Cumming DC; Hodsman AB
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4528-35. PubMed ID: 12364430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy.
    Glover SJ; Eastell R; McCloskey EV; Rogers A; Garnero P; Lowery J; Belleli R; Wright TM; John MR
    Bone; 2009 Dec; 45(6):1053-8. PubMed ID: 19679211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.
    Blumsohn A; Marin F; Nickelsen T; Brixen K; Sigurdsson G; González de la Vera J; Boonen S; Liu-Léage S; Barker C; Eastell R;
    Osteoporos Int; 2011 Jun; 22(6):1935-46. PubMed ID: 20938767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure.
    Jiang Y; Zhao JJ; Mitlak BH; Wang O; Genant HK; Eriksen EF
    J Bone Miner Res; 2003 Nov; 18(11):1932-41. PubMed ID: 14606504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are Biochemical Markers of Bone Turnover Representative of Bone Histomorphometry in 370 Postmenopausal Women?
    Chavassieux P; Portero-Muzy N; Roux JP; Garnero P; Chapurlat R
    J Clin Endocrinol Metab; 2015 Dec; 100(12):4662-8. PubMed ID: 26505821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis.
    Ma YL; Zeng Q; Donley DW; Ste-Marie LG; Gallagher JC; Dalsky GP; Marcus R; Eriksen EF
    J Bone Miner Res; 2006 Jun; 21(6):855-64. PubMed ID: 16753016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide.
    Eastell R; Krege JH; Chen P; Glass EV; Reginster JY
    Curr Med Res Opin; 2006 Jan; 22(1):61-6. PubMed ID: 16393431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
    Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.